• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: The Evolving Strategies of Generics Company Teva and the Growing Acceptance of Generic Drugs in Japan, Read More Inside 'State of the Pharmaceutical Industry, 2007'

Posted on: Wednesday, 14 March 2007, 12:01 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c52114) has announced the addition of State of the Pharmaceutical Industry, 2007 to their offering.

"Change is in the air for pharmaceutical companies as governments and judiciary work to strike a balance between ongoing business practices, patent laws, and drug price controls. 2007 will almost certainly end with harsher regulatory and legislative environments. There has never been a greater need for the pharmaceutical industry to improve its productivity and its credibility--two factors that are intimately connected with its long-term success."

--Catherine Cuddihee, M.S., Principal Director, Spectrum

Introduction

The innovator pharmaceutical industry will face many challenges in 2007. Key among them will be repairing its tarnished reputation, the growth of the generic drug industry, and the impact of the newly elected Democratic Congress. In this report, we examine these and other challenges the industry will face, the evolving strategies of generics company Teva, the launch of biogenerics into European markets, the growing acceptance of generic drugs in Japan, and opportunities for pharmaceutical companies in China.

Get the Answers You Need to Shape Your Strategy:

Many new drugs are set to launch in 2007.

What are they, and what is their sales potential?

Legislators, the judiciary, and industry are trying to strike a balance between the needs of innovator companies and generics companies and those of health care consumers and payers.

What industry business practices is the legislature planning to address in 2007?

Despite the many challenges that the pharmaceutical industry faces today, there remain areas of significant opportunity.

What are they, and how best can industry take advantage of them?

Teva is fast becoming one of the most successful pharmaceutical companies in the world.

What has been its strategy for success, and what is in its future?

Multinational pharmaceutical corporations (MPCs) are positioning themselves to benefit from the powerful growth engines known as BRIC (Brazil, Russia, India, and China). China holds the leading position in pharmaceutical market potential over Brazil, Russia, and India.

What makes China so attractive to MPCs?

Scope

Negative pharmaceutical industry dynamics: poor public perception and hostile legislative and judicial environments.

Positive pharmaceutical industry dynamics: successful licensing and marketing strategies.

Teva: steadily evolving to meet future market requirements.

Biogenerics: their near future in Europe and the United States.

The European pharmaceutical industry: European governments' efforts to encourage innovation.

The Japanese pharmaceutical industry: growth of the innovator and generic drug industries.

China: market outlook and government efforts to encourage the sale of Western pharmaceuticals.

Content Outline:

Executive Summary

Strategic Considerations

Stakeholder Implications

The Prognosis for

Current Climate of Public Distrust

PricewaterhouseCoopers Survey

Credibility of the Pharmaceutical Industry

Barrie G. James, Ph.D., Pharma Strategy Consulting

Positive Industry Dynamics

Inlicensing Technology and Late- Stage Products

Demand Is Driving Cost

Diversified Offerings vs. Targeted Ones

Inventing and Marketing New Diseases

Expected New Products and the Impact of Patent Expiries

Emerging Blockbusters and Near Blockbusters

Januvia

Galvus

Acomplia

Invega

Pristiq

Succinobucol

Cimzia

RSD-

Increasing Development Costs and Pipeline Issues

Patent Expiries

Harsher Legislative and Regulatory Climates in the United States

Patent Litigation Settlements and Patent Reform Legislation

Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill

Patent Litigation Settlements

Patent Reform Legislation

Prescription Drug User Fee Act

Increasing Potential for U.S. Drug Price Regulation

Access to Life- Saving Medicines Act

Setting the Stage for Universal Health Care Debate in

The Pharmaceutical Industry vs. the Judiciary

Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill

What Makes Teva So Successful?

The Road to Success

A Generics Powerhouse

An Innovator to Watch

The Road Ahead

Biogenerics Move on Stage

Europe Makes the First Move

John Ansell, M.A., John Ansell Consultancy

The United States Hesitates

Biogenerics Forecast, -

Rewards for Innovation--Blessing or Curse for the European Pharmaceutical Industry?

Neil Grubert, M.A., Program Manager, Spectrum, Pharmacoeconomics, Pricing,

and Reimbursement

Lost Advantage

Government Initiatives

Harmonization of Health Technology Assessments

Industry Frustration

Premiums for Innovation

Landscape for Japan's Pharmaceutical Industry

Hiroshi Tashiro, M.Sc., Research Manager of Decision Resources' Tokyo offi ce

Growth in the Japanese Pharmaceutical Market

Outlook for the Japanese Generics Market

Revision of Corporate Laws

China--A Developing Pharmaceutical Market

Why China? Why Now?

Lin (Victor) Li, Analyst, and Alice von Loesecke, Ph.D., Senior Director--New Products,

Decision Resources

Health Care Reform

State Food and Drug Administration Initiatives

Growth Drivers

Potentially Huge Drug Markets

Near- Term Opportunities

Outlook

Appendix

List of Figures

List of Tables

Companies Mentioned in This Report

Amlyn

AnorMed

Apotex

Astellas

AstraZeneca

AtheroGenics

Barr Labs

Biocraft

Biogen Idec

Biopartners

Bristol- Myers Squibb

Cardiome

Copley

Dr. Reddy's Labs

Eli Lilly

Eon Labs

Genentech

Genmab

Genzyme

GlaxoSmithKline

Hexal

Ivax

Janssen

Lundbeck

Medimmune

Merck & Co.

Merck KGaA

Millennium

Neurochem

Novartis

Novo Nordisk

Pfizer

PricewaterhouseCoopers

Roche

Sandoz

Sanofi - Aventis

Schering

Serono

Sicor

Synthon

Teva

UCB

Wyeth

For more information visit http://www.researchandmarkets.com/reports/c52114

Source: Decision Resources

Source: Business Wire

More News in this Category